PDF herunterladen
CC BY-NC-ND 4.0 · Thorac Cardiovasc Surg Rep 2022; 11(01): e23-e26
DOI: 10.1055/s-0042-1742714
Case Report: Cardiac

Lung Transplantation for Adult Respiratory Distress Syndrome after SARS-CoV-2 Infection

Achim Koch 
1   Department of Thoracic and Cardiovascular Surgery, University of Duisburg-Essen Faculty of Medicine, Essen, Northrhine-Westfalia, Germany
,
Nikolaus Pizanis
1   Department of Thoracic and Cardiovascular Surgery, University of Duisburg-Essen Faculty of Medicine, Essen, Northrhine-Westfalia, Germany
,
Vasiliki Bessa
2   Department of Pulmonology, University of Duisburg-Essen Faculty of Medicine, Essen, Northrhine-Westfalia, Germany
,
Frank Herbstreit
3   Department of Anesthesiology, University of Duisburg-Essen Faculty of Medicine, Essen, Northrhine-Westfalia, Germany
,
Erich Gulbins
4   Institute for Molecular Biology, University of Duisburg-Essen Faculty of Medicine, Essen, Northrhine-Westfalia, Germany
,
Clemens Aigner 
5   Department of Thoracic Surgery, Universitat Duisburg-Essen Medizinische Fakultat, Essen, Germany
,
Markus Kamler
6   Thorax und Kardiovaskuläre Chirurgie, Universitätsklinikum Essen, Essen, Germany
7   Herzchirurgie, Herzzentrum Essen, Essen, Germany
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Background The majority of patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection present mild symptoms. However, some patients develop severe acute respiratory distress syndrome (ARDS) and subsequent irreversible lung damage despite extracorporeal membrane oxygenation, leaving lung transplantation the ultimate therapeutically option.

Case Description Here, we report a case of lung transplantation in a 31-year-old male recipient suffering from post-coronavirus disease 2019 respiratory failure with irreversible ARDS after prolonged extracorporeal membrane oxygenation therapy.

Conclusion Patient selection criteria are elucidated. One relevant mechanism for susceptibility to SARS-CoV-2 in the respiratory system, the acid sphingomyelinase/ceramide system might be altered during infection with SARS-CoV-2.

Keywords

SARS-CoV-2 - lung transplantation - sphingosine

Authors' Contributions

Achim Koch was involved in conception of design, data acquisition, interpretation, drafting, and final approval and was accountable for all aspects of the work, and was also a corresponding author.


Nikolaus Pizanis was involved in conception of design, data acquisition, interpretation, drafting, and final approval and was accountable for all aspects of the work.


Vasiliki Bessa was involved in acquisition of data and revision and final approval and was accountable for aspects of accuracy and integrity and revision.


Frank Herbstreit was involved in acquisition of data and revision and final approval and was accountable for aspects of accuracy and integrity.


Erich Gulbins was involved in design of work and revision and final approval and was accountable for aspects of accuracy and integrity.


Clemens Aigner was involved in interpretation of data and revision and final approval and was accountable for aspects of accuracy and integrity.


Markus Kamler was involved in conception and critical revision and final approval and was accountable for aspects of accuracy and integrity.




Publikationsverlauf

Eingereicht: 31. August 2021

Angenommen: 10. November 2021

Artikel online veröffentlicht:
02. März 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Chen JY, Qiao K, Liu F. et al. Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis. Chin Med J (Engl) 2020; 133 (12) 1390-1396
    CrossrefPubMedGoogle Scholar
  • 2 Han W, Zhu M, Chen J. et al. Lung transplantation for elderly patients with end-stage COVID-19 pneumonia. Ann Surg 2020; 272 (01) e33-e34
    CrossrefPubMedGoogle Scholar
  • 3 Lang C, Jaksch P, Hoda MA. et al. Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient. Lancet Respir Med 2020; 8 (10) 1057-1060
    CrossrefPubMedGoogle Scholar
  • 4 Cypel M, Keshavjee S. When to consider lung transplantation for COVID-19. Lancet Respir Med 2020; 8 (10) 944-946
    CrossrefPubMedGoogle Scholar
  • 5 Bharat A, Querrey M, Markov NS. et al. Lung transplantation for patients with severe COVID-19. Sci Transl Med 2020; 12 (574) 4282
    CrossrefPubMedGoogle Scholar
  • 6 Bharat A, Machuca TN, Querrey M. et al. Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. Lancet Respir Med 2021; 9 (05) 487-497
    CrossrefPubMedGoogle Scholar
  • 7 Brenner EJ, Ungaro RC, Gearry RB. et al. Corticosteroids, but not TNF antagonists, are associated with adverse Covid-19 outcome in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 2020; 159 (02) 481-491.e3
    CrossrefPubMedGoogle Scholar
  • 8 Carpinteiro A, Edwards MJ, Hoffmann M. et al. Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Rep Med 2020; 1 (08) 100142
    CrossrefPubMedGoogle Scholar
  • 9 Grassmé H, Henry B, Ziobro R. et al. β1-Integrin accumulates in cystic fibrosis luminal airway epithelial membranes and decreases sphingosine, promoting bacterial infections. Cell Host Microbe 2017; 21 (06) 707-718.e8
    CrossrefPubMedGoogle Scholar
  • 10 Edwards MJ, Becker KA, Gripp B. et al. Sphingosine prevents binding of SARS-CoV-2 spike to its cellular receptor ACE2. J Biol Chem 2020; 295 (45) 15174-15182
    CrossrefPubMedGoogle Scholar